Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine - Starton Therapeutics

Drug Profile

Olanzapine - Starton Therapeutics

Alternative Names: CHEMIO OLANZ; CMIO-OLANZ; CMIO-OLNZ; STAR-OLZ - Starton Therapeutics

Latest Information Update: 24 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemioCare
  • Developer Starton Therapeutics
  • Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Piperazines; Small molecules; Thiophenes
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Chemotherapy-induced nausea and vomiting; Nausea and vomiting

Most Recent Events

  • 20 May 2024 Starton Therapeutics has patent protection for Olanzapine in the US
  • 21 Feb 2023 Phase I development is ongoing in the US
  • 21 Feb 2023 Olanzapine is available for licensing in the US (https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top